TGR(mREN2)27 rats develop non-alcoholic fatty liver disease-associated portal hypertension responsive to modulations of Janus-kinase 2 and Mas receptor.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
12 08 2019
12 08 2019
Historique:
received:
05
10
2018
accepted:
29
07
2019
entrez:
14
8
2019
pubmed:
14
8
2019
medline:
11
11
2020
Statut:
epublish
Résumé
Prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing. Resulting fibrosis and portal hypertension, as a possible secondary event, may necessitate treatment. Overexpression of mouse renin in the transgenic rat model, TGR(mREN2)27, leads to spontaneous development of NAFLD. Therefore, we used TGR(mREN2)27 rats as a model of NAFLD where we hypothesized increased susceptibility and investigated fibrosis and portal hypertension and associated pathways. 12-week old TGR(mREN2)27 rats received either cholestatic (BDL) or toxic injury (CCl
Identifiants
pubmed: 31406138
doi: 10.1038/s41598-019-48024-4
pii: 10.1038/s41598-019-48024-4
pmc: PMC6690919
doi:
Substances chimiques
Proto-Oncogene Mas
0
Proto-Oncogene Proteins
0
RNA, Messenger
0
Receptors, G-Protein-Coupled
0
Jak2 protein, rat
EC 2.7.10.2
Janus Kinase 2
EC 2.7.10.2
Renin
EC 3.4.23.15
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
11598Références
J Hepatol. 2010 Aug;53(2):372-84
pubmed: 20494470
J Hepatol. 2008 Sep;49(3):417-28
pubmed: 18486983
Eur J Clin Invest. 2012 Dec;42(12):1261-71
pubmed: 22998019
Gastroenterology. 2013 Oct;145(4):874-884.e5
pubmed: 23796456
Clin Sci (Lond). 2009 Sep 14;117(11):375-86
pubmed: 19371232
PLoS One. 2016 Sep 20;11(9):e0163069
pubmed: 27649410
Lab Invest. 2018 Oct;98(10):1263-1275
pubmed: 29326427
J Hepatol. 1997 Mar;26(3):614-20
pubmed: 9075669
Clin Gastroenterol Hepatol. 2012 Sep;10(9):1028-33.e2
pubmed: 22610002
Methods Mol Biol. 2017;1627:91-116
pubmed: 28836197
F1000Prime Rep. 2014 Oct 01;6:95
pubmed: 25374673
Eur J Clin Invest. 2012 May;42(5):526-33
pubmed: 22023532
PLoS One. 2015 Sep 25;10(9):e0138732
pubmed: 26406236
Nat Commun. 2013;4:2823
pubmed: 24264436
J Hepatol. 2000;32(1 Suppl):141-56
pubmed: 10728801
Klin Wochenschr. 1978 Apr 15;56(8):389-97
pubmed: 642412
PLoS One. 2013 Oct 21;8(10):e77817
pubmed: 24204981
Physiol Rev. 2018 Jan 1;98(1):505-553
pubmed: 29351514
Gastroenterology. 2008 May;134(6):1655-69
pubmed: 18471545
Gut. 2004 May;53(5):744-9
pubmed: 15082595
Dig Dis Sci. 2016 Jul;61(7):2102-7
pubmed: 26993824
Hepatol Res. 2013 Nov;43(11):1241-50
pubmed: 23448275
Gut. 2017 Jan;66(1):145-155
pubmed: 26385087
Gut. 2017 Jan;66(1):180-190
pubmed: 27646933
Dig Liver Dis. 2015 Apr;47(4):315-23
pubmed: 25637451
Liver Int. 2015 Mar;35(3):979-85
pubmed: 24905085
J Cell Biochem. 2016 Mar;117(3):638-46
pubmed: 26280784
J Hepatol. 2010 Oct;53(4):702-12
pubmed: 20633948
PLoS One. 2012;7(4):e32785
pubmed: 22509248
Lab Invest. 2012 Oct;92(10):1428-39
pubmed: 22890552
J Hepatol. 2015 Sep;63(3):743-52
pubmed: 26047908
Gastroenterology. 2001 Aug;121(2):389-95
pubmed: 11487548
Am J Gastroenterol. 2008 May;103(5):1152-8
pubmed: 18422814
Hepatology. 2014 Jul;60(1):334-48
pubmed: 24619965
J Chin Med Assoc. 2012 Oct;75(10):501-8
pubmed: 23089401